SCHEMBL3566922

SCHEMBL3566922

CC(C)(C)OC(=O)CC(=O)c1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.54
FEN1 P39748 1/20 0.54
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
KDM4E B2RXH2 1/20 0.49
RAB9A P51151 1/20 0.49
POLB P06746 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
ALDH1A1 P00352 4/20 0.43
HTT P42858 1/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL853580 0.83 ERCC5 (0.61) ERCC5FEN1MEN1KMT2ALMNA
SCHEMBL30335736 0.83 ERCC5 (0.61) ERCC5FEN1MEN1KMT2ALMNA
SCHEMBL1885649 0.82 NPC1 (0.51) MEN1KMT2ALMNAKDM4ERAB9A
SCHEMBL6542055 0.80 ACLY (0.43) MEN1KMT2ALMNAKDM4EPOLB
SCHEMBL18787732 0.79 NPC1 (0.60) KMT2ALMNARAB9AALDH1A1HTT
SCHEMBL31388564 0.79 ERCC5 (0.56) ERCC5FEN1MEN1KMT2ALMNA
SCHEMBL952091 0.79 ERCC5 (0.56) ERCC5FEN1MEN1KMT2ALMNA
SCHEMBL29987169 0.78 ERCC5 (0.74) ERCC5FEN1MEN1KMT2ALMNA
SCHEMBL27806654 0.78 CES2 (0.52) KMT2ALMNARAB9APOLBCES2
SCHEMBL31439626 0.77 ERCC5 (0.54) ERCC5FEN1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825278-B2 Substituted enaminones, their derivatives and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-11-02 US disclosed
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US disclosed
EP-1742904-A4 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2007-04-18 EP disclosed
EP-1742904-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-17 EP disclosed
WO-2005108347-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof GABRB2, GABRB1, GABRB3 ERCC5 3312/4885FEN1 4236/4885MEN1 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.